title: Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.
abstract: OBJECTIVE
  We evaluate terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome.
  
  
  METHODS
  The study included 100, 20 to-50-year-old subjects who met the consensus criteria for chronic prostatitis/chronic pelvic pain syndrome and had not received previous alpha-blockers. Subjects were randomized to receive terazosin with dose escalation from 1 to 5 mg. daily or placebo for 14 weeks. The primary criterion for response was scoring 2 or less ("delighted-to-mostly satisfied") on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life item. The secondary criterion for response was greater than 50% reduction in NIH-CPSI pain score at 14 weeks. Other outcomes included total and NIH-CPSI domain scores, International Prostate Symptom Score, peak urinary flow rate, post-void residual urine and adverse effects.
  
  
  RESULTS
  Using the primary criterion 24 of 43 evaluable subjects (56%) responded in the terazosin group compared to 14 of 43 (36%) in the placebo group (p = 0.03). Using the secondary criterion 26 of 43 subjects (60%) responded in the terazosin group compared to 16 of 43 (37%) in the placebo group (p = 0.03). The terazosin group had greater reductions (p <0.05) in NIH-CPSI total score, individual domain scores and International Prostate Symptom Score than the placebo group. There was no difference in peak urinary flow rate or post-void residual. In the terazosin group 18 patients (42%) had side effects compared to 9 (21%) in the placebo group (p = 0.04).
  
  
  CONCLUSIONS
  Terazosin proved superior to placebo for patients with chronic prostatitis/chronic pelvic pain syndrome who had not received alpha-blockers previously.
authors.affiliation: School of Pharmaceutical Sciences, University of Science Malaysia, Penang, Malaysia.
authors.forename: Phaik Yeong
authors.initials: PY
authors.lastname: Cheah
authors.forename: Men Long
authors.initials: ML
authors.lastname: Liong
authors.forename: Kah Hay
authors.initials: KH
authors.lastname: Yuen
authors.forename: Chu Leong
authors.initials: CL
authors.lastname: Teh
authors.forename: Timothy
authors.initials: T
authors.lastname: Khor
authors.forename: Jin Rong
authors.initials: JR
authors.lastname: Yang
authors.forename: Hin Wai
authors.initials: HW
authors.lastname: Yap
authors.forename: John N
authors.initials: JN
authors.lastname: Krieger
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D002908:Chronic Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D017699:Pelvic Pain / Q000188:drug therapy* / Q000209:etiology; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011472:Prostatitis / Q000150:complications / Q000188:drug therapy*; D013577:Syndrome
chemical_list: D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin